This phenomenon is supported by numerous studies highlighting that coagulation deficiencies, reflected by reduced prothrombin activity, are associated with an increased risk of fatal complications in patients with COVID-19 (Connors & Levy, 2020) [9]. This evidence concerns the gene F2 and COVID-19.